No, cefixime 800 mg is NOT recommended as first-line treatment for gonorrhea
Cefixime is no longer recommended as a first-line regimen for gonorrhea treatment at any dose, including 800 mg, due to declining susceptibility and treatment failures, particularly for pharyngeal infections. 1
Current First-Line Recommendation
The standard of care is ceftriaxone 250 mg intramuscularly PLUS azithromycin 1 g orally as a single dose (or doxycycline 100 mg orally twice daily for 7 days). 1
Why Cefixime Is No Longer First-Line
Rising minimum inhibitory concentrations (MICs): From 2006-2011, there was a significant increase in N. gonorrhoeae isolates with elevated cefixime MICs, particularly in the Western United States and among men who have sex with men 1
Poor pharyngeal efficacy: A 400 mg oral dose of cefixime demonstrates limited efficacy for pharyngeal gonorrhea and does not provide bactericidal levels as high or sustained as ceftriaxone 250 mg IM 1
Treatment failures documented: Recent clinical trials show cefixime 800 mg plus doxycycline failed to achieve noninferiority to ceftriaxone plus azithromycin, with all treatment failures occurring in pharyngeal infections 2
Resistance concerns: The prevalence of cefixime-resistant N. gonorrhoeae has exceeded 6% in some regions, surpassing the WHO's 5% resistance threshold 3
When Cefixime 400 mg May Be Used (Not 800 mg)
Cefixime can only be considered as an alternative regimen when ceftriaxone is unavailable:
- Dose: Cefixime 400 mg orally (not 800 mg) 1
- Must be combined with: Azithromycin 1 g orally OR doxycycline 100 mg twice daily for 7 days 1
- Mandatory follow-up: Test-of-cure at 1 week is required 1
FDA Labeling Context
The FDA label for cefixime indicates approval for uncomplicated gonorrhea (cervical/urethral) at 400 mg as a single oral dose 4. However, this labeling predates current CDC guidance that no longer recommends cefixime as first-line therapy due to emerging resistance patterns.
Critical Pitfalls to Avoid
Do not use cefixime for pharyngeal gonorrhea: Even at 800 mg, efficacy is inadequate 2, 5
Do not use cefixime monotherapy: Always combine with azithromycin or doxycycline 1
Do not skip test-of-cure: If cefixime is used, culture or NAAT at 1 week is mandatory 1
Do not use 800 mg dosing: While studied in research settings 2, 6, 7, the 800 mg dose is not part of current treatment guidelines and showed treatment failures
Why This Matters for Morbidity and Mortality
Using suboptimal therapy risks:
- Treatment failure leading to ongoing transmission
- Progression to complications: Pelvic inflammatory disease, ectopic pregnancy, infertility in women 1
- Facilitation of HIV transmission 1
- Accelerated development of cephalosporin resistance, potentially compromising ceftriaxone—the last highly effective single-dose treatment 1
The CDC explicitly states that continued use of cefixime might hasten resistance development to ceftriaxone, making preservation of ceftriaxone effectiveness critical for public health 1.